Several discoveries about leprosy indicate that Mycobacterium leprae transmission mainly occurs by inhalation, and the nose is major port of entry and exit. The present study evaluated the clinical application of PCR for detection of M. leprae DNA in nasal mucosa biopsies in untreated leprosy patients (52) and their contacts (99) from the State Reference Center in Sanitary Dermatology and Leprosy, Uberlândia, MG, Brazil. PCR detection of a 372-base pair DNA fragment from M. leprae was accomplished in 36 (69.2%) patients, from which 34 (91.9%) of them were multibacillaries. Furthermore, PCR was positive in 3 (16.7%) of 18 slit-skin smear negative, 4 (25.0%) of 16 skin lesion BI negative, 8 (33.3%) of 24 nasal mucosa BI negative patients, and 10 of 99 contacts (10.1%). The presence of bacilli in 10.1% of the contacts may potentially reflect an occult leprosy, and these patients must be accompanied, followed by a chemoprophylaxy treatment. Considering all PCR results against clinical and BI classification of patients and controls, we have found a sensitivity of 69.2%, a specificity of 89.9%, and an accuracy of 82.8%. It has been demonstrated here through PCR of nasal biopsies that the bacillus invades the mucosa, passing through the nasal inferior turbinate to reach peripheral blood. Therefore, the molecular investigation of invasive nasal biopsies by PCR tests has proven to be useful in defining patients of higher risk of transmission and risk-group contacts, which is an important step to reach the World Health Organization objective towards the elimination of leprosy as a public health problem.
Introduction
Leprosy, a chronic disease caused by Mycobacterium leprae, is one of the oldest infectious diseases ascribed to man that even today affects over 515,000 new patients each year worldwide [1] . However, epidemiological data does not measure the real extension of the problem. It has been demonstrated, using serological assays for determination of specific antibodies, that M. leprae infection is much more frequent than the number of known clinical cases [2] .
The accurate diagnosis of leprosy is of fundamental importance to all aspects of leprosy epidemiology, case management, and prevention of disability [3] . The recent development of polymerase chain reaction (PCR) has brought an unprecedented opportunity for sensitive, specific, and rapid detection of M. leprae in clinical specimens [4, 5] .
As the most accepted hypothesis is that the initial infection by M. leprae occurs in nasal mucosa [6, 7] , various clinical specimens from this tissue were extensively evaluated by PCR and have been proven of value [8] [9] [10] . Nonetheless, none of these previous investigations evaluated an invasive nasal specimen for M. leprae detection. We hypothesized that the nasal inferior turbinate infection is a secondary event in the disease development, post mucosa colonization by M. leprae. Therefore, this invasive procedure must be investigated to demonstrate the migration of the bacillus within the tissue.
In the present study, therefore, we aimed to evaluate the clinical application of PCR for detection M. leprae in nasal inferior turbinate biopsies in untreated leprosy patients and their contacts.
Subjects and methods

Collection of clinical specimens
Patients (52) and their contacts (79) were selected in the Leprosy Ambulatory, at the State Reference Center in Sanitary Dermatology, Federal University of Uberlândia, MG, Brazil. Patients were classified clinically and histopathologically, according to Ridley and Jopling [11] scale as indeterminate (I), tuberculoid (TT), borderline-tuberculoid (BT), borderline-borderline (BB), borderline-lepromatous (BL), and lepromatous (LL), and according to World Health Organization (WHO) [12] as paucibacillary (PB) or multibacillary (MB). Furthermore, Mitsuda test, slit-skin smear, and skin lesion biopsy were performed.
Contacts were defined as people who live or have lived with leprosy patients in the five previous years to the diagnosis. They were submitted to clinical examination and laboratorial tests. There were no dermatologic or neurologic findings. Additionally, the bacilloscopic index (BI) of slit-skin smears and nasal mucosa biopsy were negative. Thus, we have considered them as nonleprosy carriers. The BI of slit-skin smears of contacts was obtained from ear lobes and elbows, and stained by the method of Ziehl-Neelseen. The only difference in the collection procedure between patients and contacts was the additional sampling from lesions in those patients who presented them.
This investigation was carried out under the approval of the Federal University of Uberlândia Research Ethics Committee number 025/2000. All patients, contacts, and controls have agreed to participate in this research by signing an informed consent form.
Nasal mucosa biopsy was performed using nasal speculum number 3 and frontal mirror. A small pledget of cotton wool soaked with 0.5 ml of 2% tetracaine solution and 0.5 ml of 1:1.000 epinephrine was placed along the inferior nasal turbinate for 10 min. Soon after, 0.5 ml of 2% lidocaine with 1:200,000 epinephrine was infiltrated 1-2 cm to anterior curved edge of the inferior turbinate. Biopsy of this area was performed with a small oval punch forceps, obtaining a specimen of the nasal mucosa of approximately 2.0 · 1.5 · 0.5 mm (Fig. 1) . To avoid bleeding after the biopsy, gauze with neomycin ointment was placed over the biopsy area. The subject was instructed to remove the package after a few hours and once home. All subjects were advised to rest as much as possible for the rest of the day and warned that the nose may ooze blood during this time [13] .
For both skin and nasal biopsies, only one sample was obtained from each subject, and before storage and further analyses, the tissue was split into two pieces. For accomplishment of PCR, the tissue was immediately conditioned in a sterilized aluminum foil and dived in liquid nitrogen. For histopathologic examination, the tissue was fixed in 10% buffered formalin.
DNA extraction and PCR amplification for clinical specimens
Frozen biopsy specimens were fragmented with steel razors and incubated at 55°C in a 300 ll of a Proteinase K solution for 15 h. Soon after that, 550 ll of balanced phenol in Tris-HCl (pH 8.0) and 250 ll of Tris-HCl (1 M, pH 8.0) were added, homogenized and left on ice Fig. 1 . External view of a nasal mucosa (inferior turbinate) biopsy procedure using a nasal speculum number 3, small oval punch forceps, and frontal mirror. for 5 min. Then, 110 ll of chloroform:isoamyl alcohol (24:1) was added, the solution was homogenized by inversion, and again it was left on ice by 10 min. After centrifugation (10,000g at 4°C) for 5 min, the aqueous phase (up to 600 l) was collected, mixed with 1400 ll of absolute ethanol, and incubated at À20°C for at least 8 h. The tubes were centrifuged (15,000g at 4°C) for 15 min. The pellets were washed in 75% ethanol by centrifugation (7500g at 4°C) for 5 min, then, resuspended in 50 ll of deionized water, and stored at À20°C.
Primers amplifying the 372-base pair (bp) fragment found in the M. leprae RLEP3 sequence X17153 DNA [14, 15] were used following parameters proposed by Yoon et al. [5] . These primers can detect as low as 1-100 bacilli with specificity near 100% [5] . PCR conditions were: denaturation at 95°C for 5 min, 30 cycles of denaturation at 95°C, annealing at 58°C for 40 s, primer extension at 72°C for 40 s, and final extension at 72°C for 10 min. Reagents were: 1.5 mM MgCl 2 , 1 U Taq DNA polymerase, 200 lM dNTP, and 7 pmol of each primer. It was also co-amplified in each reaction a constitutive marker of a 200-bp fragment of the NRAMP1 gene promoter region (GenBank AJ535670) as a positive control for each reaction (forward: 5 0 -CTCGCATTAGGCCAACGA and reverse: 5 0 -TTCTGTGCCTCCCAAGTTAGC). Results of the optimization were published elsewhere [16] . After amplification was finished, the reaction mixture was run in a 1.5% agarose gel. After electrophoresis, the gel was stained with ethidium bromide and the 372-bp fragment was examined under the UV illumination (Fig. 2) .
Results
Fifty-two untreated leprosy patients were selected for the present study (Table 1) . Of these, 37 (71.2%) were MB and 15 (28.8%) were PB. Slit-skin smear was positive in 34 (65.4%) patients (three slit-skin smear negative patients were MB because they presented five or more skin lesions and/or involvement of more than one peripheral nerve, according to WHO classification) [12] . Histopathological examination of skin lesions found positive BI in 36 (69.2%) patients and negative BI in 16 (30.8%). In nasal mucosa, the pathologist found a positive BI in 28 (53.8%) patients and a negative BI in 24 (46.2%).
PCR detection of DNA from M. leprae was accomplished in 36 (69.2%) patients. In MB group, PCR was positive in 34 (91.9%) samples, and in PB patients, it was positive in 2 (13.3%). Furthermore, PCR could detect DNA from M. leprae in nasal mucosa sample of 3 (16.7%) of 18 slit-skin smear negative patients, 4 (25.0%) of 16 skin lesion BI negative patients, and 8 (33.3%) of 24 nasal mucosa BI negative patients.
All 28 (100.0%) nasal mucosa BI positive patients had positive PCR in nasal mucosa sample. PCR could not detect DNA from M. leprae in 1 (3.0%) of 33 slit-skin smear positive patients and 4 (11.1%) of 36 skin lesion BI positive patients.
In the contacts group, PCR of nasal mucosa was positive in 10 of 99 samples (10.1%). Of these, 9 (90.0%) were contacts of MB patients and 1 (10.0%) was contact of a PB patient. All 99 contacts were slit-skin smear negative and presented negative BI in nasal mucosa.
Considering all PCR results against clinical and BI classification of patients and controls, we have found a sensitivity of 69.2%, a specificity of 89.9%, and an accuracy of 82.8% overall.
Discussion
Traditionally, diagnosis and classification of leprosy have been based on clinical examination in association with information from skin-smears. The WHO Expert Committee on Leprosy at its seventh meeting in 1997 [17] defined a case of leprosy as follows: ''A case of leprosy is a person having one or more of the following features, and who has still to complete a full course of treatment: hypopigmented or reddish skin lesion(s) with definite loss of sensation; involvement of the peripheral nerves, as demonstrated by definite thickening with loss of sensation; and skin-smear positive for acid-fast bacilli''.
This simplified strategy for diagnosis, which could be used in especially difficult situations, and is being routinely applied in many national programs, may lead to significant under diagnosis, particularly of MB disease. Under diagnosis of MB patients is important for three main reasons: MB cases are considered the major source of infection, so further transmission of M. leprae may occur; MB patients may succumb to preventive disability, with the accompanying psychosocial sequel, because they are at greater risk of reactions and consequent nerve damage; MDT (multi-drug therapy) will not be effective if MB patients are treated as PB.
Skin-smears are considered one of the cardinal signs of leprosy and, in association to clinical examination, the ''gold standard'' for leprosy diagnosis. The specificity of this examination approaches 100%. However, the sensitivity of smears alone is low, because smear-positive patients rarely represent more than 50%, and, sometimes as few as 10% of all patients (as it detects at least 10 4 bacilli/g). In addition, there is no information about viability and infectivity of the organisms detected [3, 18] . Histopathologic examination cannot be regarded as the gold standard. Even in the best hands, a significant proportion of clinically obvious patients will yield negative or doubtful histopathologic pictures [19] . Serological tests (anti-PGL-I antibodies) also present great specificity, but lacks sensitivity [20] . Even when a satisfactory immunodetection is achieved, it may only reflect a past infection and not supply information on bacteriological status. The culture of M. leprae is not possible, what is also a great obstacle to researches in this area.
Recent development of the PCR technique brought an unprecedented opportunity for fast, sensitive and specific detection of M. leprae in human beings. It was described initially for this pathogen in 1989 [14, 21] , being shown an useful and applicable method, and ever since it has been used in the most different clinical specimens as skin [4, 5] , nasal swab [8] [9] [10] , bucal swab [10] , and hair bulb [9] .
In the present study, PCR was used to amplify sequences of the DNA of M. leprae in biopsies of nasal mucosa. We opted for this clinical specimen because several publications have demonstrated that the nose plays the main role in this bacillus transmission [6, 7] and that early leprosy involvement can be found in nasal mucosa even before lesions become apparent in the skin, nerves, or other parts of the body [22, 23] . Until now, no previous work had evaluated PCR in an invasive nasal specimen.
The efficiency and/or practicality of this procedure are not discussed; however, this is a very common and successful procedure for investigation in otorhinolaryngology area, with less than 1% of complications. The main point in this paper is to prove that the bacillus invades the mucosa, passing through the nasal inferior turbinate, reaching peripheral blood circulation with systemic symptoms.
The ideal diagnostic test would be simple, would identify all cases (100% sensitivity), and would be negative in people who do not have leprosy (100% specificity) [3] . There is no such isolated method for leprosy. We could detect DNA from M. leprae in 36 (69.2%) of our patients, and 34 (91.9%) of our MB samples. These rates are superior to those encountered for slit-skin smears and histopathology examination in the literature (10-50%) [3, 18, 19] . Additionally, among those positive PCR patients, we could detect M. leprae DNA in 3 (16.7%) negative slit-skin smear patients, 4 (25.0%) with negative BI in skin lesion biopsies, and in 8 (33.3%) negative BI samples of nasal mucosa. Overall, there were 3 (5.8%) in 52 cases in which PCR of nasal mucosa biopsy was the only positive test (patients number 2, 40, and 51 from Table 1 ). Based on these results, positive PCR nasal mucosa biopsies in PB may indicate that these patients could play an important role in the chain of transmission and support the twofold higher chance of PBÕs contacts being infected than the non-contacts population [24] .
Classification in PB or MB cases is required because there are two treatment regimens. Untreated or imprecisely treated MB patients are probably the most important source of transmission of M. leprae. Several studies have shown that these patients excrete large quantities of bacilli from the nose and mouth [24] . On the other hand, there is increasing evidence that subclinical transmission may occur. DNA sequences from M. leprae have been isolated in nasal swabs and secretions from many apparently healthy individuals residing in endemic areas, and large proportion of those who live in these areas have been shown to demonstrate seropositivity against M. leprae-specific antigens [2, 25] .
Nonetheless, no previous work applying PCR have proven that those microorganisms have already invaded the nasal mucosa, since only non-invasive tests were accomplished until the present moment [8, 19, 10] . Thus, it is justified nasal mucosa biopsy of contacts of leprosy patients and PCR application with the objective of detecting an early infection without clinical manifestations.
Additionally, it is possible that nasal swab collection may present some misinterpretation of results, once the mucosa is the primary site of contact of any microorganisms, even without an infection establishment. This implies that positive results in swabs may not agree with biopsy results. In our study, we have found 46.3% of agreement between them, which may indicate different stages of infection. Furthermore, we have detected, through PCR, 13.7% positive nasal mucosa biopsies in which were negative in nasal swab (data not shown).
In the present study, PCR of nasal mucosa was positive in 10 contacts (10.1%). And more important, all 99 patients were slit-skin smear negative and presented negative BI in nasal mucosa. As the primers initially designed by Woods and Cole [14] amplify a 372-bp DNA product derived only from M. leprae, PCR specificity is 100% [5] . The gold standard is rarely infallible, so the results will always possess a degree of error. Thus, we believe that these 10 samples reflect potentially leprosy patients that should be accompanied and may receive chemoprophylaxy treatment.
Identification of the initial point of infection is the most important and difficult problem in the study of M. leprae transmission. PCR seems to be very promising to measure subclinical infection with satisfactory sensitivity and specificity [2] . Most of the contacts may develop a subclinical infection that usually do not establish in more than 95%, so that no clinical manifestation of the disease develops [26] . Possibly, a number of non-defined asymptomatic infected individuals exist and they may have an active role in the transmission of the disease [27] .
In contacts of leprosy patients, we could identify these potentially transmitters of the bacillus, people who can be involved in the dynamic process of the development of the disease, constituting target-groups for new prevention strategies.
Conclusions
Results of this investigation illustrate the potential diagnostic value of PCR tests in nasal mucosa biopsies of leprosy patients and their contacts. The higher sensitivity, specificity, and accuracy of the test in untreated leprosy patients are comparable, or even superior, to other methods described in the medical literature. Additionally, we have identified the presence of bacilli in 10.1% of the contacts, which may potentially reflect a subclinical leprosy infection, and these patients must be accompanied, followed by a chemoprophylaxy treatment.
The molecular investigation of invasive nasal biopsies by PCR has proven to be useful in defining patients of higher risk of transmission and risk-group contacts, an important step to reach the World Health Assembly objective towards the elimination of leprosy as a public health problem.
